» Articles » PMID: 32868492

Mitochondrial Dysfunction in Kidney Injury, Inflammation, and Disease: Potential Therapeutic Approaches

Overview
Specialty Nephrology
Date 2020 Sep 2
PMID 32868492
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondria are energy-producing organelles that not only satisfy the high metabolic demands of the kidney but sense and respond to kidney injury-induced oxidative stress and inflammation. Kidneys are rich in mitochondria. Mitochondrial dysfunction plays a critical role in the progression of acute kidney injury and chronic kidney disease. Mitochondrial responses to specific stimuli are highly regulated and synergistically modulated by tightly interconnected processes, including mitochondrial dynamics (fission, fusion) and mitophagy. The counterbalance between these processes is essential in maintaining a healthy network of mitochondria. Recent literature suggests that alterations in mitochondrial dynamics are implicated in kidney injury and the progression of kidney diseases. A decrease in mitochondrial fusion promotes fission-induced mitochondrial fragmentation, but a reduction in mitochondrial fission produces excessive mitochondrial elongation. The removal of dysfunctional mitochondria by mitophagy is crucial for their quality control. Defective mitochondrial function disrupts cellular redox potential and can cause cell death. Mitochondrial DNA derived from damaged cells also act as damage-associated molecular patterns to recruit immune cells and the inflammatory response can further exaggerate kidney injury. This review provides a comprehensive overview of the role of mitochondrial dysfunction in acute kidney injury and chronic kidney disease. We discuss the processes that control mitochondrial stress responses to kidney injury and review recent advances in understanding the role of mitochondrial dysfunction in inflammation and tissue damage through the use of different experimental models of kidney disease. We also describe potential mitochondria-targeted therapeutic approaches.

Citing Articles

Global research trends on the associations between chronic kidney disease and mitochondria: insights from the bibliometric analysis.

Tang X, Zhang A, Feng X, Wang W, Chen F, Tao Y Int Urol Nephrol. 2025; .

PMID: 40019610 DOI: 10.1007/s11255-025-04437-x.


Is High-Dose Ubiquinone Therapy Before Cardiac Surgery Enough to Reduce the Incidence of Cardiac Surgery-Associated Acute Kidney Injury? A Randomized Controlled Trial.

Vucemilovic H, Kovac R, Stanisic L, Sanader Vucemilovic A, Mrcela D, Benzon B Antioxidants (Basel). 2025; 14(2).

PMID: 40002427 PMC: 11852363. DOI: 10.3390/antiox14020243.


Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments.

Hu Y, Zhang Y, Jiang W Clin Exp Med. 2025; 25(1):57.

PMID: 39954162 PMC: 11829913. DOI: 10.1007/s10238-025-01584-4.


Effects of Graphene Quantum Dots on Renal Fibrosis Through Alleviating Oxidative Stress and Restoring Mitochondrial Membrane Potential.

Kim K, Park J, An J, Bae G, Kim K, Park S Adv Sci (Weinh). 2024; 12(10):e2410747.

PMID: 39739624 PMC: 11904958. DOI: 10.1002/advs.202410747.


RTN1A mediates diabetes-induced AKI-to-CKD transition.

Min L, Chen Y, Chen Y, Zhong F, Ni Z, Gu L JCI Insight. 2024; 9(24).

PMID: 39704174 PMC: 11665580. DOI: 10.1172/jci.insight.185826.


References
1.
Bhatia D, Chung K, Nakahira K, Patino E, Rice M, Torres L . Mitophagy-dependent macrophage reprogramming protects against kidney fibrosis. JCI Insight. 2019; 4(23). PMC: 6962025. DOI: 10.1172/jci.insight.132826. View

2.
Honda T, Hirakawa Y, Nangaku M . The role of oxidative stress and hypoxia in renal disease. Kidney Res Clin Pract. 2019; 38(4):414-426. PMC: 6913586. DOI: 10.23876/j.krcp.19.063. View

3.
Martins de Brito O, Scorrano L . Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature. 2008; 456(7222):605-10. DOI: 10.1038/nature07534. View

4.
Tait S, Oberst A, Quarato G, Milasta S, Haller M, Wang R . Widespread mitochondrial depletion via mitophagy does not compromise necroptosis. Cell Rep. 2013; 5(4):878-85. PMC: 4005921. DOI: 10.1016/j.celrep.2013.10.034. View

5.
Podrini C, Cassina L, Boletta A . Metabolic reprogramming and the role of mitochondria in polycystic kidney disease. Cell Signal. 2019; 67:109495. DOI: 10.1016/j.cellsig.2019.109495. View